Are Peptides Legal in Louisiana? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Louisiana as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Louisiana attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Louisiana statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Louisiana has scheduled or banned on its own. The Louisiana Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Louisiana at a glance

State controlled-substances law: Louisiana Uniform Controlled Dangerous Substances Law, La. R.S. 40:961 et seq.; schedules at R.S. 40:964 (codes.findlaw.com)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (La. R.S. 40:964, Schedule III(E)) (codes.findlaw.com)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: In spring 2023 the Louisiana Board of Pharmacy warned in-state compounders, and out-of-state pharmacies shipping into Louisiana, to stop compounding with unapproved forms of semaglutide, specifically semaglutide sodium salt, which its executive director described as a cheaper research-grade form not intended for human use; pharmacies may compound only with bulk substances that comply with FDA rules, and the warning was not a ban on compounding semaglutide base. No formal board rule or order was located; the position rests on a contemporaneous NBC News report quoting the board (2023-05) (nbcnews.com)
Medical board on peptide prescribing: No statement located
GLP-1 by telehealth: Restricted for weight loss. The Louisiana State Board of Medical Examiners' telemedicine rule (LAC 46:XLV.7513(C)) says a physician shall not use telemedicine to treat obesity under the board's weight-control medication rules, nor chronic non-cancer pain, and may prescribe controlled substances by telemedicine only after an in-person visit within the past year. A Louisiana physician therefore cannot prescribe a GLP-1 for obesity by telemedicine under the board's rule; diabetes prescribing is not covered by the prohibition. The rule text should be checked against the board's current version. (law.cornell.edu)
State-level enforcement, 2023 to 2026: 1 action found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Louisiana, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Louisiana:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Louisiana. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Louisiana law adds

Louisiana's controlled-substances law (Louisiana Uniform Controlled Dangerous Substances Law, La. R.S. 40:961 et seq.; schedules at R.S. 40:964) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (codes.findlaw.com)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Louisiana's schedules or in a Louisiana-specific ban as of September 2026. That is the position in most states.

Human growth hormone

None of the five schedules in R.S. 40:964 names human growth hormone, somatropin, hCG or any peptide; Schedule III(E) covers testosterone-related anabolic steroids only. (La. R.S. 40:964, Schedule III(E)) (codes.findlaw.com)

Compounded semaglutide and tirzepatide

2023-05. In spring 2023 the Louisiana Board of Pharmacy warned in-state compounders, and out-of-state pharmacies shipping into Louisiana, to stop compounding with unapproved forms of semaglutide, specifically semaglutide sodium salt, which its executive director described as a cheaper research-grade form not intended for human use; pharmacies may compound only with bulk substances that comply with FDA rules, and the warning was not a ban on compounding semaglutide base. No formal board rule or order was located; the position rests on a contemporaneous NBC News report quoting the board. (nbcnews.com)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

No Louisiana medical board guidance specific to peptide therapy was located. A Louisiana prescriber who administers BPC-157 or another unapproved peptide is exposed under the state's medical practice act and, since the FDA's 2026 letters, under federal law; the July 2026 advisory vote has not changed that yet.

Buying, possessing and using research peptides in Louisiana

Unscheduled research peptides are not controlled dangerous substances, but La. R.S. 40:1060.13 makes it unlawful to sell, deliver or possess any legend drug except on a practitioner's prescription, a misdemeanor, so possessing a prescription-only peptide such as semaglutide without a prescription is a state offence while peptides that are not prescription drugs fall outside it. (codes.findlaw.com)

Ordering from a vendor in another state. Almost every research-peptide order into Louisiana is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Restricted for weight loss. The Louisiana State Board of Medical Examiners' telemedicine rule (LAC 46:XLV.7513(C)) says a physician shall not use telemedicine to treat obesity under the board's weight-control medication rules, nor chronic non-cancer pain, and may prescribe controlled substances by telemedicine only after an in-person visit within the past year. A Louisiana physician therefore cannot prescribe a GLP-1 for obesity by telemedicine under the board's rule; diabetes prescribing is not covered by the prohibition. The rule text should be checked against the board's current version. (law.cornell.edu) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Louisiana law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Louisiana

2025-02-19. Louisiana's attorney general signed the 38-state letter urging the FDA to act against counterfeit and research-only GLP-1 sales. (naag.org)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. The board's semaglutide-salt position could not be opened as a primary letter or order; the pharmacy board's site refused connections. The telemedicine obesity prohibition text is a 2017 version and should be confirmed against the current rules.

Frequently asked questions

Is BPC-157 legal in Louisiana?

Louisiana has not scheduled BPC-157, so possessing it is not a Louisiana offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Louisiana?

Restricted for weight loss. The Louisiana State Board of Medical Examiners' telemedicine rule (LAC 46:XLV.7513(C)) says a physician shall not use telemedicine to treat obesity under the board's weight-control medication rules, nor chronic non-cancer pain, and may prescribe controlled substances by telemedicine only after an in-person visit within the past year. A Louisiana physician therefore cannot prescribe a GLP-1 for obesity by telemedicine under the board's rule; diabetes prescribing is not covered by the prohibition. The rule text should be checked against the board's current version. The Louisiana Board of Pharmacy position on compounded versions: In spring 2023 the Louisiana Board of Pharmacy warned in-state compounders, and out-of-state pharmacies shipping into Louisiana, to stop compounding with unapproved forms of semaglutide, specifically semaglutide sodium salt, which its executive director described as a cheaper research-grade form not intended for human use; pharmacies may compound only with bulk substances that comply with FDA rules, and the warning was not a ban on compounding semaglutide base. No formal board rule or order was located; the position rests on a contemporaneous NBC News report quoting the board.

Is HGH legal in Louisiana?

Only with a valid prescription for an approved use. Louisiana does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Louisiana fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.